Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Your aging cells may be working against you. Researchers at Sanford Burnham Prebys and Mayo Clinic have uncovered how so-called "zombie" cells use faulty mitochondria to keep inflammation switched on long after it should stop. Blocking one key metabolic signal reduced inflammation and improved healthy aging in mice — pointing to a promising new therapeutic strategy.
As we age, certain cells stop dividing but refuse to die — earning them the nickname "zombie" cells, or senescent cells. These cells remain metabolically active and continuously pump out inflammatory molecules (a process called SASP), contributing to frailty, cardiovascular disease, cancer, and neurodegeneration. Scientists have long known these cells are troublemakers, but the exact mechanism driving their inflammatory behavior has been murky — until now.
A new study published in Nature by researchers at Sanford Burnham Prebys and Mayo Clinic reveals that two separate mitochondrial processes team up to keep inflammation running. First, dysfunctional mitochondria in senescent cells overproduce acetyl-CoA, a metabolic molecule that loosens the packaging around inflammatory genes — essentially unlocking the door. Second, damaged mitochondria leak DNA and RNA into the cell, triggering immune alarm signals that then walk right through that open door to activate those genes. The team tested a drug called CTPI-2 that blocks acetyl-CoA production, and found it reduced inflammation across multiple tissues and improved healthspan in mice — even though the immune alarm signals were still present.
Key Takeaways
Why it matters: Chronic inflammation is a root driver of many age-related diseases. This discovery opens a new therapeutic avenue — targeting metabolism rather than eliminating senescent cells outright — which could lead to treatments that help people stay healthier longer.
